U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C20H30O2
Molecular Weight 302.451
Optical Activity UNSPECIFIED
Defined Stereocenters 7 / 7
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MIBOLERONE

SMILES

C[C@@H]1CC2=CC(=O)CC[C@@H]2[C@H]3CC[C@@]4(C)[C@@H](CC[C@]4(C)O)[C@H]13

InChI

InChIKey=PTQMMNYJKCSPET-OMHQDGTGSA-N
InChI=1S/C20H30O2/c1-12-10-13-11-14(21)4-5-15(13)16-6-8-19(2)17(18(12)16)7-9-20(19,3)22/h11-12,15-18,22H,4-10H2,1-3H3/t12-,15+,16-,17+,18-,19+,20+/m1/s1

HIDE SMILES / InChI

Molecular Formula C20H30O2
Molecular Weight 302.451
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 7 / 7
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: Description was created based on several sources, including http://www.skylocke.com/pdf_txt/CHEQUE-Drops.PDF | https://www.ncbi.nlm.nih.gov/pubmed/18515094 | https://anabolic.org/cheque-drops-mibolerone/

Mibolerone is a synthetic anabolic steroid. It binds both androgen and progesterone receptors and exerts both androgenic and progestagenic actions. Mibolerone (CHEQUE® Drops) was used in veterinary for estrous (heat) prevention in adult female dogs not intended primarily for breeding purposes. No prescription preparation, human or veterinary, is currently known to contain mibolerone worldwide.

Approval Year

PubMed

PubMed

TitleDatePubMed
Effects of treatment with androgen receptor ligands on microRNA expression of prostate cancer cells.
2015-07-03
A novel anticancer agent, retigeric acid B, displays proliferation inhibition, S phase arrest and apoptosis activation in human prostate cancer cells.
2010-12-05
Androgens modulate autophagy and cell death via regulation of the endoplasmic reticulum chaperone glucose-regulated protein 78/BiP in prostate cancer cells.
2010-09-09
Androgen receptor mutations associated with androgen insensitivity syndrome: a high content analysis approach leading to personalized medicine.
2009-12-09
Manipulating prohibitin levels provides evidence for an in vivo role in androgen regulation of prostate tumours.
2009-12
Regulation of growth hormone receptors in human prostate cancer cell lines.
2009-10-15
Novel C-6 substituted and unsubstituted pregnane derivatives as 5alpha-reductase inhibitors and their effect on hamster flank organs diameter size.
2009-10
Aromatic esters of progesterone as 5alpha-reductase and prostate growth inhibitors.
2009-06
In vivo and in vitro effect of novel 4,16-pregnadiene-6,20-dione derivatives, as 5alpha-reductase inhibitors.
2008-09
Synthesis and biological effect of halogen substituted phenyl acetic acid derivatives of progesterone as potent progesterone receptor antagonists.
2008-09
Biological activity of novel progesterone derivatives having a bulky ester side chains at C-3.
2008-09
Antiproliferative actions of the synthetic androgen, mibolerone, in breast cancer cells are mediated by both androgen and progesterone receptors.
2008-06
Steroid and beta-adrenergic receptor modifications in target organs of broiler chickens fed with a diet containing beta2-adrenergic agents.
2008-06
Androgen receptor functional analyses by high throughput imaging: determination of ligand, cell cycle, and mutation-specific effects.
2008
Steroids with a carbamate function at C-17, a novel class of inhibitors for human and hamster steroid 5alpha-reductase.
2007-10
Oriental herbs as a source of novel anti-androgen and prostate cancer chemopreventive agents.
2007-09
Expression and function of the human androgen-responsive gene ADI1 in prostate cancer.
2007-08
Discovery of antiandrogen activity of nonsteroidal scaffolds of marketed drugs.
2007-07-17
Estrogen signaling and disruption of androgen metabolism in acquired androgen-independence during cadmium carcinogenesis in human prostate epithelial cells.
2007-02-01
Contraception in felids.
2006-07-01
Perillyl alcohol inhibits the expression and function of the androgen receptor in human prostate cancer cells.
2006-05-18
COMPRENDO: Focus and approach.
2006-04
Collision-induced dissociation pathways of anabolic steroids by electrospray ionization tandem mass spectrometry.
2006-04
[Regulation of expression of pituitary tumor transforming gene 1 (PTTG1) by androgen in prostate cancer].
2005-12-18
Stem/progenitor and intermediate cell types and the origin of human prostate cancer.
2005-12
Acquisition of androgen independence by human prostate epithelial cells during arsenic-induced malignant transformation.
2005-09
Involvement of transcription factor Sp1 in quercetin-mediated inhibitory effect on the androgen receptor in human prostate cancer cells.
2005-04
The Estradiol-Dihydrotestosterone model of prostate cancer.
2005-03-18
Androgen-induced mineralization by MC3T3-E1 osteoblastic cells reveals a critical window of hormone responsiveness.
2005-03-18
Studies of targeting and intracellular trafficking of an anti-androgen doxorubicin-formaldehyde conjugate in PC-3 prostate cancer cells bearing androgen receptor-GFP chimera.
2004-11-04
Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
2004-10-01
Estimation of estrogenic and antiestrogenic activities of selected pesticides by MCF-7 cell proliferation assay.
2004-05
Methyl selenium metabolites decrease prostate-specific antigen expression by inducing protein degradation and suppressing androgen-stimulated transcription.
2004-05
Dexamethasone enhances the cytotoxic effect of radioiodine therapy in prostate cancer cells expressing the sodium iodide symporter.
2004-03
Forced expression of heat-shock protein 70 increases the secretion of Hsp70 and provides protection against tumour growth.
2004-02-23
Probasin promoter (ARR(2)PB)-driven, prostate-specific expression of the human sodium iodide symporter (h-NIS) for targeted radioiodine therapy of prostate cancer.
2003-11-15
Androgens inhibit estradiol-17beta synthesis in Atlantic croaker (Micropogonias undulatus) ovaries by a nongenomic mechanism initiated at the cell surface.
2003-11
Study of 202 natural, synthetic, and environmental chemicals for binding to the androgen receptor.
2003-10
Suppression of prostate tumor growth by U19, a novel testosterone-regulated apoptosis inducer.
2003-08-01
The use of androgen receptor amino/carboxyl-terminal interaction assays to investigate androgen receptor gene mutations in subjects with varying degrees of androgen insensitivity.
2003-05
Effects of a diphenyl ether-type herbicide, chlornitrofen, and its amino derivative on androgen and estrogen receptor activities.
2003-04
The F-box protein SKP2 mediates androgen control of p27 stability in LNCaP human prostate cancer cells.
2002-08-20
Role of androgens in female genital sexual arousal: receptor expression, structure, and function.
2002-04
The human ovarian surface epithelium is an androgen responsive tissue.
2002-03-18
Effect of geldanamycin on androgen receptor function and stability.
2002-01
Expression of the human androgen receptor in eukaryotic cells using a recombinant adenovirus vector yields high levels of the soluble, functional receptor protein.
2001-12
Regulation of u-PA gene expression in human prostate cancer.
2001-11-01
Melatonin elicits nuclear exclusion of the human androgen receptor and attenuates its activity.
2001-10-01
Characterization of intracellular aggregates using fluorescently-tagged polyglutamine-expanded androgen receptor.
2001-07
Activation of androgen receptor in epidermal growth factor modulation of fetal mouse sexual differentiation.
1996-10-14
Patents

Sample Use Guides

CHEQUE® DROPS mibolerone 100 ug/ml female dogs: 1 to 25 lbs - 30 ug, 26 to 50 lbs - 60 ug, 51 to 100 lbs - 120 ug, 101 and over lbs - 180 ug orally once each day by adding to a small amount of food or directly to the mouth
Route of Administration: Oral
Whereas high physiological doses (10-100nM) of 5alpha-dihydrotestosterone reduced E(2)-mediated induction of the estrogen-regulated gene progesterone receptor (PR) to basal levels, mibolerone at lower doses (1nM) eliminated PR expression, suggesting that mibolerone may also act via the PR.
Substance Class Chemical
Created
by admin
on Wed Apr 02 07:04:39 GMT 2025
Edited
by admin
on Wed Apr 02 07:04:39 GMT 2025
Record UNII
9OGY4BOR8D
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
MIBOLERONE CIII
USP-RS  
Preferred Name English
MIBOLERONE
GREEN BOOK   INN   MART.   MI   USAN   USP  
INN   USAN  
Official Name English
NSC-72260
Code English
MIBOLERONE [GREEN BOOK]
Common Name English
MIBOLERONE [MI]
Common Name English
U-10,997
Code English
U-10997
Code English
17?-Hydroxy-7?,17-dimethylestr-4-en-3-one
Systematic Name English
MIBOLERONE [USP MONOGRAPH]
Common Name English
MIBOLERONE [USAN]
Common Name English
MIBOLERONE [MART.]
Common Name English
MIBOLERONE CIII [USP-RS]
Common Name English
U-10-997
Code English
MATENON
Brand Name English
ESTR-4-EN-3-ONE, 17-HYDROXY-7,17-DIMETHYL-, (7.ALPHA.,17.BETA.)-
Common Name English
DIHYDROLONE
Common Name English
CHEQUE DROPS
Brand Name English
CHEQUE
Brand Name English
mibolerone [INN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C243
Created by admin on Wed Apr 02 07:04:39 GMT 2025 , Edited by admin on Wed Apr 02 07:04:39 GMT 2025
CFR 21 CFR 520.1430
Created by admin on Wed Apr 02 07:04:39 GMT 2025 , Edited by admin on Wed Apr 02 07:04:39 GMT 2025
WIKIPEDIA Designer-drugs-Mibolerone
Created by admin on Wed Apr 02 07:04:39 GMT 2025 , Edited by admin on Wed Apr 02 07:04:39 GMT 2025
DEA NO. 4000
Created by admin on Wed Apr 02 07:04:39 GMT 2025 , Edited by admin on Wed Apr 02 07:04:39 GMT 2025
CFR 21 CFR 558.348
Created by admin on Wed Apr 02 07:04:39 GMT 2025 , Edited by admin on Wed Apr 02 07:04:39 GMT 2025
Code System Code Type Description
EVMPD
SUB08941MIG
Created by admin on Wed Apr 02 07:04:39 GMT 2025 , Edited by admin on Wed Apr 02 07:04:39 GMT 2025
PRIMARY
INN
3203
Created by admin on Wed Apr 02 07:04:39 GMT 2025 , Edited by admin on Wed Apr 02 07:04:39 GMT 2025
PRIMARY
PUBCHEM
251636
Created by admin on Wed Apr 02 07:04:39 GMT 2025 , Edited by admin on Wed Apr 02 07:04:39 GMT 2025
PRIMARY
DRUG BANK
DB11429
Created by admin on Wed Apr 02 07:04:39 GMT 2025 , Edited by admin on Wed Apr 02 07:04:39 GMT 2025
PRIMARY
MESH
C100075
Created by admin on Wed Apr 02 07:04:39 GMT 2025 , Edited by admin on Wed Apr 02 07:04:39 GMT 2025
PRIMARY
ChEMBL
CHEMBL425863
Created by admin on Wed Apr 02 07:04:39 GMT 2025 , Edited by admin on Wed Apr 02 07:04:39 GMT 2025
PRIMARY
SMS_ID
100000081184
Created by admin on Wed Apr 02 07:04:39 GMT 2025 , Edited by admin on Wed Apr 02 07:04:39 GMT 2025
PRIMARY
NSC
72260
Created by admin on Wed Apr 02 07:04:39 GMT 2025 , Edited by admin on Wed Apr 02 07:04:39 GMT 2025
PRIMARY
CAS
3704-09-4
Created by admin on Wed Apr 02 07:04:39 GMT 2025 , Edited by admin on Wed Apr 02 07:04:39 GMT 2025
PRIMARY
CHEBI
34849
Created by admin on Wed Apr 02 07:04:39 GMT 2025 , Edited by admin on Wed Apr 02 07:04:39 GMT 2025
PRIMARY
EPA CompTox
DTXSID4036489
Created by admin on Wed Apr 02 07:04:39 GMT 2025 , Edited by admin on Wed Apr 02 07:04:39 GMT 2025
PRIMARY
RS_ITEM_NUM
1443362
Created by admin on Wed Apr 02 07:04:39 GMT 2025 , Edited by admin on Wed Apr 02 07:04:39 GMT 2025
PRIMARY
NCI_THESAURUS
C72100
Created by admin on Wed Apr 02 07:04:39 GMT 2025 , Edited by admin on Wed Apr 02 07:04:39 GMT 2025
PRIMARY
ECHA (EC/EINECS)
223-046-5
Created by admin on Wed Apr 02 07:04:39 GMT 2025 , Edited by admin on Wed Apr 02 07:04:39 GMT 2025
PRIMARY
FDA UNII
9OGY4BOR8D
Created by admin on Wed Apr 02 07:04:39 GMT 2025 , Edited by admin on Wed Apr 02 07:04:39 GMT 2025
PRIMARY
WIKIPEDIA
MIBOLERONE
Created by admin on Wed Apr 02 07:04:39 GMT 2025 , Edited by admin on Wed Apr 02 07:04:39 GMT 2025
PRIMARY
MERCK INDEX
m7523
Created by admin on Wed Apr 02 07:04:39 GMT 2025 , Edited by admin on Wed Apr 02 07:04:39 GMT 2025
PRIMARY Merck Index
Related Record Type Details
ACTIVE MOIETY